Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1681)

MAJOR TRANSACTION FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to (i) the announcement dated 23 November 2015 (the "Announcement") of the Company in relation to the Fourth Round Acquisition which constitutes a major transaction of the Company under Chapter 14 of the Listing Rules, (ii) the announcement dated 11 December 2015 of the Company in relation to the delay in despatch of circular and (iii) the announcement dated 21 January 2016 (the "Delay Announcements") of the Company in relation to the further delay in despatch of circular. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Delay Announcements, the circular containing, among other things, further details of the Fourth Round Acquisition and notice of the EGM approving the Fourth Round Acquisition (the "Circular"), will be despatched to the Shareholders on or before 31 March 2016.

As additional time is required to finalise certain information to be included in the Circular, the date of despatch of the Circular is expected to be postponed to on or before 30 June 2016.

By order of the Board

Consun Pharmaceutical Group Limited

AN Yubao

Chairman

Hong Kong, 31 March 2016

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.